Clinical Trial

Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis

Terminated
View on ClinicalTrials.gov →
Why the trial stopped
Terminated early due to lack of expected efficacy. Three participants were enrolled but none completed the study.
Summary
The goal of this clinical trial is to investigate the efficacy and safety of Deucravacitinib in patients with moderate-to-severe palmoplantar pustulosis. Approximately 25 subjects will be included in the study and receive Deucravacitinib 6mg per day for four months. This study will begin June 2025 and is expected to last 14 months.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-24.
Status change: Not Yet Recruiting → Terminated 2026-03-09
Trial Details
NCT Number NCT07000630
Lead Sponsor Peking University First Hospital
Conditions Palmoplantar Pustulosis
Enrollment 3 participants
Start Date 2025-06-20
Primary Completion 2025-11-30 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-11